Dashboard
1
The company has declared Negative results for the last 3 consecutive quarters
- NET PROFIT(Q) At CNY 68.84 MM has Fallen at -63.33%
- ROCE(HY) Lowest at 3.71%
- DEBT-EQUITY RATIO (HY) Highest at 26.41 %
2
With ROE of 3.08%, it has a expensive valuation with a 1.19 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
CNY 22,827 Million (Large Cap)
45.00
NA
0.31%
0.26
3.08%
1.25
Revenue and Profits:
Net Sales:
4,022 Million
(Quarterly Results - Jun 2026)
Net Profit:
894 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
24.15%
0%
24.15%
6 Months
-13.79%
0%
-13.79%
1 Year
30.14%
0%
30.14%
2 Years
120.36%
0%
120.36%
3 Years
121.35%
0%
121.35%
4 Years
155.41%
0%
155.41%
5 Years
-46.52%
0%
-46.52%
Intco Medical Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-12.22%
EBIT Growth (5y)
-39.02%
EBIT to Interest (avg)
45.38
Debt to EBITDA (avg)
0.54
Net Debt to Equity (avg)
-0.30
Sales to Capital Employed (avg)
0.29
Tax Ratio
20.80%
Dividend Payout Ratio
9.46%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
12.85%
ROE (avg)
23.59%
Valuation key factors
Factor
Value
P/E Ratio
45
Industry P/E
Price to Book Value
1.37
EV to EBIT
27.64
EV to EBITDA
16.72
EV to Capital Employed
1.30
EV to Sales
2.90
PEG Ratio
NA
Dividend Yield
0.28%
ROCE (Latest)
4.69%
ROE (Latest)
3.08%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
4,022.00
2,887.00
39.31%
Operating Profit (PBDIT) excl Other Income
1,623.60
738.40
119.88%
Interest
108.50
96.40
12.55%
Exceptional Items
-41.90
-257.40
83.72%
Consolidate Net Profit
893.70
10.60
8,331.13%
Operating Profit Margin (Excl OI)
332.70%
156.90%
17.58%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 39.31% vs 15.43% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 8,331.13% vs -88.91% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
9,884.60
9,509.00
3.95%
Operating Profit (PBDIT) excl Other Income
1,841.20
1,751.40
5.13%
Interest
383.30
322.20
18.96%
Exceptional Items
318.70
245.80
29.66%
Consolidate Net Profit
1,047.20
1,491.70
-29.80%
Operating Profit Margin (Excl OI)
90.60%
93.30%
-0.27%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 3.95% vs 38.79% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -29.80% vs 284.36% in Dec 2024
About Intco Medical Technology Co., Ltd. 
Intco Medical Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






